Genetic testing rates, practices and trends for ovarian cancer patients in the PARP inhibitor era

被引：0
|
作者：
Folsom, Susan [1 ]
O'Brien, Emily [1 ]
Narayan, Jeyani [2 ]
McGough, Christine [1 ]
Lesnock, Jamie [1 ]
Sukumvanich, Paniti [1 ]
Rush, Shannon [1 ]
Berger, Jessica [1 ]
Courtney-Brooks, Madeleine [1 ]
Taylor, Sarah [1 ]
机构：
[1] Univ Pittsburgh Med Ctr, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
来源：
GYNECOLOGIC ONCOLOGY | 2023年 / 176卷
关键词：
D O I：
10.1016/j.ygyno.2023.06.281
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2158
引用
收藏
页码：S231 / S232
页数：2
相关论文
共 50 条
  • [31] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Ying Chen
    Lei Zhang
    Quan Hao
    Archives of Gynecology and Obstetrics, 2013, 288 : 367 - 374
  • [32] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [33] Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
    Wakefield, Matthew John
    Nesic, Ksenija
    Kondrashova, Olga
    Scott, Clare L.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1872 (02):
  • [34] "Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment
    Smith, Anna Jo Bodurtha
    O'Brien, Caroline
    Haggerty, Ashley
    Ko, Emily M.
    Rendle, Katharine A.
    GYNECOLOGIC ONCOLOGY, 2024, 186 : 170 - 175
  • [35] Same day service: Using a genetic testing station and video counseling to improve genetic testing rates among ovarian cancer patients
    Marjon, Nicole
    Guerra, Rosa Alisa
    FreemanJana, Alexandra
    Ueda, Stefanie M.
    Chen, Lee-may
    Mak, Julie
    GYNECOLOGIC ONCOLOGY, 2020, 159 (02) : E29 - E29
  • [36] Germline and somatic genetic testing in ovarian cancer patients
    Chandrasekaran, D.
    Manchanda, R.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 125 (11) : 1460 - 1460
  • [37] A retrospective analysis of real-world tumor BRCA (tBRCA) testing trends in ovarian cancer (OC) before and after PARP inhibitor approvals
    Randall, L. M.
    Aydin, E.
    Louie-Gao, M.
    Hazard, S.
    Westin, S. N.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 809 - 810
  • [38] Trends in frontline PARP inhibitor maintenance in advanced epithelial ovarian cancer across the United States.
    Huelsmann, Erica
    Deng, Mengying
    Handorf, Elizabeth A.
    Chu, Christina
    Jain, Angela
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [39] Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study
    Lahelma, Mari
    Rauhamaa, Heini
    Leskela, Riikka-Leena
    Isomeri, Outi
    Idanpaan-Heikkila, Juhana
    Kakela, Sari
    Roebuck, Nichola
    Mascialino, Barbara
    Hietanen, Sakari
    Loukovaara, Mikko
    Auranen, Annika
    ACTA ONCOLOGICA, 2024, 63 : 763 - 771
  • [40] Combining PARP inhibitor with TACC3 inhibition overcomes PARP inhibitor resistance in ovarian cancer
    Wu, Yu
    Wang, Qilong
    Deng, Chaolin
    Li, Mo
    Xiao, Yinan
    CANCER RESEARCH, 2024, 84 (06)
12345